Repligen Corp (OQ:RGEN)

Business Focus: Medical Equipment, Supplies & Distribution

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution
 
See Regulatory Filings on SEC
Company Contact
Address: BUILDING 1, SUITE 100, 41 SEYON STREET
WALTHAM MA 02453
Tel: N/A
Website: https://www.repligen.com
IR: See website
<
Key People
Olivier Loeillot
President, Chief Commercial Officer
Tony John Hunt
Chief Executive Officer, Director
Jason K. Garland
Chief Financial Officer
James R. Bylund
Chief Operating Officer
Christine Gebski
Senior Vice President of Filtration and Chromatography
Ralf Kuriyel
Senior Vice President - Research and Development
Business Overview
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. The Company's bioprocessing business consists of four main franchises: filtration (including fluid management); chromatography; process analytics, and proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. The Company's chromatography franchise includes a number of products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. The Company's TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes.
Financial Overview
For the fiscal year ended 31 December 2023, Repligen Corp revenues decreased 20% to $638.8M. Net income decreased 78% to $41.6M. Revenues reflect Product revenue - Filtration products segment decrease of 30% to $347.8M, Product revenue - Protein products segment decrease of 9% to $103.5M, North America segment decrease of 18% to $281.1M, Europe segment decrease of 20% to $236.3M.
Employees: 1,783 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $8,598M as of Dec 31, 2023
Annual revenue (TTM): $638.76M as of Dec 31, 2023
EBITDA (TTM): $160.72M as of Dec 31, 2023
Net annual income (TTM): $41.58M as of Dec 31, 2023
Free cash flow (TTM): $74.93M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 55,838,548 as of Mar 18, 2024
Index Membership: S&P 400 Mid Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.